Literature DB >> 9483915

[Bronchopulmonary manifestations of gastroenterologic and hepatic diseases].

A Tromm1, G H Micklefield, D Hüppe.   

Abstract

Topics of this review are the bronchopulmonary manifestations of gastroesophageal reflux disease, cirrhosis of the liver and chronic inflammatory bowel diseases. About 20% of patients with chronic obstructive airway disease show evidence of gastroesophageal reflux disease. Reflux bronchoconstriction seems to be of greater importance than microaspiration. First studies show the positive effects of acid inhibition by proton pump inhibitors on pulmonary symptoms. Hepatorenal syndrome is characterized by arterial hypoxemia with PaO2-values < 70 mm Hg. Different mediators (endotoxins, amines, polypeptides or allergens) are discussed. Furthermore, elevated levels of prostacycline, atrial natriuretic factor and platelet activating factor have been described. Recently published studies focused on the role of nitric oxide (NO). Patients with cirrhosis of the liver show a higher rate of a pathologically elevated airway resistance which might be induced by a reduced histamine clearance. Ascites leads to reversible restrictive airway disease. Bronchopulmonary manifestations in chronic inflammatory bowel diseases include obstructive and restrictive airway diseases, vascular or serosal changes and show low clinical evidence. In contrast, pathological changes of the common function tests were found in 30 to 50%. These findings may be induced by circulating immune complexes, vasculitis, increased permeability or a combined immune reaction of both, the bronchial and intestinal mucosa. Undesired effects of salicylates should be taken into account. This review shows that bronchopulmonary manifestations in diseases of the Gl-tract or the liver are more common than usually known and should be taken into clinical consideration.

Entities:  

Mesh:

Year:  1997        PMID: 9483915     DOI: 10.1007/BF03044668

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  49 in total

1.  [Systemic manifestations of liver cirrhosis. Heart, circulation, lung].

Authors:  H Schomerus; R Heinrich
Journal:  Z Gastroenterol Verh       Date:  1986-04

2.  Omeprazole for the treatment of posterior laryngitis.

Authors:  L P Leite; B T Johnston; D O Castell
Journal:  Am J Med       Date:  1995-12       Impact factor: 4.965

Review 3.  [Gastroesophageal reflux and lung diseases].

Authors:  R Keller; A Breitenbücher
Journal:  Pneumologie       Date:  1990-02

4.  Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis.

Authors:  F S Daoud; J T Reeves; J W Schaefer
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

5.  Pharyngeal aspiration in normal adults and patients with depressed consciousness.

Authors:  E J Huxley; J Viroslav; W R Gray; A K Pierce
Journal:  Am J Med       Date:  1978-04       Impact factor: 4.965

6.  The role of the vague nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention.

Authors:  L E Mansfield; H H Hameister; H S Spaulding; N J Smith; N Glab
Journal:  Ann Allergy       Date:  1981-12

Review 7.  Epidemiology of gastro-esophageal reflux disease.

Authors:  P J Howard; R C Heading
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

8.  The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients.

Authors:  A J Greenstein; H D Janowitz; D B Sachar
Journal:  Medicine (Baltimore)       Date:  1976-09       Impact factor: 1.889

9.  Recurrent pulmonary disease in children: a complication of gastroesophageal reflux.

Authors:  A R Euler; W J Byrne; M E Ament; E W Fonkalsrud; C T Strobel; S C Siegel; R M Katz; G S Rachelefsky
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

10.  Pulmonary abnormalities in Crohn's disease.

Authors:  J B Neilly; A N Main; C McSharry; J Murray; R I Russell; F Moran
Journal:  Respir Med       Date:  1989-11       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.